Candace Hillary Feldman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lupus Erythematosus, Systemic | 47 | 2023 | 2104 | 8.210 |
Why?
|
Rheumatology | 14 | 2023 | 576 | 4.480 |
Why?
|
Rheumatic Diseases | 12 | 2023 | 593 | 4.140 |
Why?
|
Antirheumatic Agents | 12 | 2022 | 1338 | 2.800 |
Why?
|
Lupus Nephritis | 11 | 2020 | 310 | 2.410 |
Why?
|
Medicaid | 23 | 2022 | 2737 | 2.370 |
Why?
|
Hydroxychloroquine | 11 | 2023 | 412 | 2.260 |
Why?
|
Medication Adherence | 10 | 2022 | 2063 | 1.990 |
Why?
|
Insurance Benefits | 4 | 2021 | 183 | 1.960 |
Why?
|
Healthcare Disparities | 9 | 2021 | 3154 | 1.380 |
Why?
|
Azathioprine | 4 | 2021 | 354 | 1.360 |
Why?
|
Mycophenolic Acid | 4 | 2021 | 343 | 1.300 |
Why?
|
Immunosuppressive Agents | 9 | 2021 | 4153 | 1.240 |
Why?
|
Musculoskeletal Diseases | 2 | 2023 | 581 | 1.190 |
Why?
|
Medically Underserved Area | 2 | 2020 | 253 | 0.980 |
Why?
|
Vaccines | 2 | 2024 | 823 | 0.940 |
Why?
|
Vaccination | 4 | 2023 | 3279 | 0.890 |
Why?
|
Primary Ovarian Insufficiency | 1 | 2021 | 115 | 0.720 |
Why?
|
Ambulatory Care | 2 | 2021 | 2708 | 0.720 |
Why?
|
Family Planning Services | 1 | 2021 | 263 | 0.650 |
Why?
|
Health Status Disparities | 2 | 2020 | 1796 | 0.650 |
Why?
|
Papillomavirus Vaccines | 2 | 2015 | 491 | 0.630 |
Why?
|
Kidney Failure, Chronic | 4 | 2022 | 2535 | 0.630 |
Why?
|
Arthritis, Rheumatoid | 3 | 2022 | 3712 | 0.620 |
Why?
|
Contraception | 1 | 2021 | 359 | 0.620 |
Why?
|
Community Networks | 1 | 2019 | 203 | 0.610 |
Why?
|
Opportunistic Infections | 1 | 2021 | 389 | 0.610 |
Why?
|
Neutrophil Activation | 5 | 2013 | 186 | 0.600 |
Why?
|
Glucocorticoids | 5 | 2023 | 2108 | 0.580 |
Why?
|
Hot Temperature | 1 | 2022 | 1356 | 0.570 |
Why?
|
Patient Acceptance of Health Care | 4 | 2021 | 3020 | 0.550 |
Why?
|
United States | 37 | 2023 | 69872 | 0.550 |
Why?
|
Cyclophosphamide | 3 | 2021 | 2242 | 0.530 |
Why?
|
Adult Survivors of Child Abuse | 1 | 2019 | 260 | 0.530 |
Why?
|
Awareness | 1 | 2019 | 640 | 0.510 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2023 | 941 | 0.510 |
Why?
|
Gout | 1 | 2021 | 573 | 0.500 |
Why?
|
Communicable Disease Control | 1 | 2021 | 856 | 0.490 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2021 | 3922 | 0.480 |
Why?
|
Health Services Accessibility | 3 | 2020 | 5135 | 0.480 |
Why?
|
Patient Care | 1 | 2020 | 640 | 0.470 |
Why?
|
Infertility | 1 | 2021 | 655 | 0.470 |
Why?
|
Vulnerable Populations | 1 | 2019 | 686 | 0.460 |
Why?
|
Humans | 97 | 2024 | 744366 | 0.450 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2016 | 387 | 0.430 |
Why?
|
Physician Executives | 1 | 2013 | 128 | 0.430 |
Why?
|
Patient Selection | 2 | 2022 | 4216 | 0.430 |
Why?
|
Adult | 54 | 2023 | 214052 | 0.430 |
Why?
|
Catastrophization | 1 | 2015 | 316 | 0.400 |
Why?
|
Urban Health Services | 1 | 2012 | 179 | 0.400 |
Why?
|
Neutrophils | 9 | 2013 | 3721 | 0.390 |
Why?
|
Middle Aged | 43 | 2022 | 213390 | 0.380 |
Why?
|
Qualitative Research | 6 | 2021 | 2682 | 0.370 |
Why?
|
Community Health Centers | 1 | 2013 | 430 | 0.360 |
Why?
|
Social Class | 2 | 2019 | 1997 | 0.360 |
Why?
|
Hospitalization | 10 | 2022 | 10259 | 0.350 |
Why?
|
Female | 57 | 2023 | 380193 | 0.340 |
Why?
|
Focus Groups | 4 | 2021 | 1321 | 0.340 |
Why?
|
Residence Characteristics | 1 | 2019 | 2050 | 0.340 |
Why?
|
Health Resources | 1 | 2015 | 911 | 0.340 |
Why?
|
Medicare | 4 | 2023 | 6566 | 0.340 |
Why?
|
Young Adult | 23 | 2022 | 56429 | 0.340 |
Why?
|
Aged | 27 | 2023 | 163288 | 0.320 |
Why?
|
Adolescent | 25 | 2022 | 85779 | 0.310 |
Why?
|
Renal Dialysis | 2 | 2022 | 1783 | 0.310 |
Why?
|
Politics | 1 | 2014 | 791 | 0.310 |
Why?
|
Education, Medical, Graduate | 1 | 2020 | 2291 | 0.300 |
Why?
|
Pregnancy Complications | 1 | 2021 | 2861 | 0.300 |
Why?
|
Male | 47 | 2023 | 350115 | 0.290 |
Why?
|
Minority Groups | 2 | 2022 | 1221 | 0.290 |
Why?
|
Sex Factors | 7 | 2019 | 10400 | 0.280 |
Why?
|
Risk Factors | 21 | 2023 | 72296 | 0.270 |
Why?
|
Incidence | 13 | 2021 | 20952 | 0.270 |
Why?
|
Indians, North American | 3 | 2021 | 355 | 0.270 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 7914 | 0.260 |
Why?
|
Streptolysins | 4 | 2011 | 55 | 0.260 |
Why?
|
Cardiovascular Diseases | 5 | 2021 | 15160 | 0.250 |
Why?
|
Risk Assessment | 9 | 2021 | 23336 | 0.250 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2016 | 2020 | 0.240 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2015 | 1458 | 0.230 |
Why?
|
Boston | 3 | 2023 | 9312 | 0.220 |
Why?
|
Prevalence | 6 | 2021 | 15221 | 0.210 |
Why?
|
Papillomavirus Infections | 1 | 2014 | 1587 | 0.210 |
Why?
|
Autoimmune Diseases | 1 | 2014 | 2134 | 0.210 |
Why?
|
Health Policy | 1 | 2014 | 2661 | 0.210 |
Why?
|
Insurance | 1 | 2023 | 111 | 0.210 |
Why?
|
Haiti | 1 | 2024 | 553 | 0.200 |
Why?
|
Proportional Hazards Models | 9 | 2021 | 12356 | 0.200 |
Why?
|
Research Design | 2 | 2019 | 5984 | 0.200 |
Why?
|
Health Status | 1 | 2014 | 4034 | 0.200 |
Why?
|
Nurses | 2 | 2021 | 2462 | 0.190 |
Why?
|
Chicago | 1 | 2021 | 240 | 0.190 |
Why?
|
Habits | 1 | 2021 | 139 | 0.190 |
Why?
|
Longitudinal Studies | 5 | 2019 | 13991 | 0.180 |
Why?
|
Cohort Studies | 13 | 2021 | 40559 | 0.180 |
Why?
|
Trust | 2 | 2021 | 505 | 0.180 |
Why?
|
Severity of Illness Index | 7 | 2021 | 15535 | 0.180 |
Why?
|
Chronic Disease | 3 | 2021 | 9145 | 0.180 |
Why?
|
Pain | 1 | 2015 | 4988 | 0.170 |
Why?
|
Databases, Factual | 4 | 2019 | 7730 | 0.170 |
Why?
|
Stress Disorders, Post-Traumatic | 3 | 2022 | 4266 | 0.170 |
Why?
|
Community-Based Participatory Research | 1 | 2021 | 214 | 0.170 |
Why?
|
Current Procedural Terminology | 1 | 2019 | 92 | 0.170 |
Why?
|
Antibodies, Antinuclear | 1 | 2020 | 326 | 0.170 |
Why?
|
Leukotriene B4 | 3 | 2011 | 294 | 0.160 |
Why?
|
Comorbidity | 3 | 2022 | 10388 | 0.160 |
Why?
|
Oximetry | 1 | 2021 | 471 | 0.160 |
Why?
|
Delphi Technique | 1 | 2021 | 779 | 0.150 |
Why?
|
Prednisone | 1 | 2022 | 1574 | 0.150 |
Why?
|
Geographic Information Systems | 1 | 2019 | 281 | 0.150 |
Why?
|
Documentation | 1 | 2023 | 871 | 0.150 |
Why?
|
Renal Artery | 1 | 2019 | 399 | 0.150 |
Why?
|
Rural Population | 2 | 2020 | 2207 | 0.150 |
Why?
|
Kidney Tubules | 1 | 2019 | 488 | 0.150 |
Why?
|
Delivery of Health Care | 2 | 2014 | 5321 | 0.140 |
Why?
|
New York City | 4 | 2023 | 710 | 0.140 |
Why?
|
Time Factors | 5 | 2021 | 40075 | 0.140 |
Why?
|
Patients | 1 | 2022 | 900 | 0.140 |
Why?
|
Chemokines | 1 | 2020 | 970 | 0.130 |
Why?
|
Massachusetts | 2 | 2022 | 8662 | 0.130 |
Why?
|
Public Opinion | 1 | 2019 | 477 | 0.130 |
Why?
|
Pilot Projects | 2 | 2018 | 8319 | 0.130 |
Why?
|
N-Formylmethionine Leucyl-Phenylalanine | 5 | 2010 | 222 | 0.130 |
Why?
|
International Classification of Diseases | 1 | 2019 | 867 | 0.120 |
Why?
|
Prenatal Care | 1 | 2021 | 1092 | 0.120 |
Why?
|
Poisson Distribution | 1 | 2015 | 513 | 0.120 |
Why?
|
Algorithms | 3 | 2019 | 13882 | 0.120 |
Why?
|
Diabetes Complications | 1 | 2020 | 1359 | 0.110 |
Why?
|
Sex Distribution | 2 | 2022 | 2297 | 0.110 |
Why?
|
Eye Diseases | 1 | 2018 | 669 | 0.110 |
Why?
|
Drug Prescriptions | 2 | 2019 | 1637 | 0.110 |
Why?
|
Impetigo | 1 | 2012 | 8 | 0.110 |
Why?
|
Pamphlets | 1 | 2012 | 75 | 0.110 |
Why?
|
Personal Autonomy | 1 | 2014 | 298 | 0.110 |
Why?
|
Cause of Death | 3 | 2021 | 3582 | 0.100 |
Why?
|
Women's Health | 1 | 2021 | 2034 | 0.100 |
Why?
|
Lung Diseases, Obstructive | 1 | 1993 | 316 | 0.100 |
Why?
|
Urban Population | 1 | 2020 | 2022 | 0.100 |
Why?
|
Multivariate Analysis | 2 | 2015 | 12244 | 0.100 |
Why?
|
Motivation | 1 | 2021 | 1971 | 0.100 |
Why?
|
Consensus | 1 | 2021 | 2960 | 0.100 |
Why?
|
Self-Help Groups | 1 | 2012 | 190 | 0.100 |
Why?
|
Patient Participation | 1 | 2020 | 1457 | 0.100 |
Why?
|
Community-Institutional Relations | 1 | 2012 | 204 | 0.100 |
Why?
|
Information Dissemination | 1 | 2019 | 1099 | 0.100 |
Why?
|
Pregnancy Outcome | 1 | 2021 | 2795 | 0.100 |
Why?
|
Self Efficacy | 1 | 2014 | 615 | 0.090 |
Why?
|
Natural Language Processing | 1 | 2019 | 1041 | 0.090 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2000 | 2282 | 0.090 |
Why?
|
Administration, Oral | 1 | 2018 | 3914 | 0.090 |
Why?
|
Diabetes Mellitus | 2 | 2019 | 5749 | 0.090 |
Why?
|
Adaptation, Psychological | 1 | 2021 | 2575 | 0.090 |
Why?
|
Child, Preschool | 5 | 2022 | 41005 | 0.090 |
Why?
|
Leadership | 1 | 2019 | 1357 | 0.090 |
Why?
|
Alcohol Drinking | 2 | 2020 | 3966 | 0.090 |
Why?
|
Smoking | 3 | 2022 | 8987 | 0.090 |
Why?
|
Ethanolamines | 1 | 2010 | 158 | 0.090 |
Why?
|
Age Factors | 4 | 2015 | 18373 | 0.090 |
Why?
|
Leukotriene Antagonists | 1 | 2010 | 127 | 0.090 |
Why?
|
Social Isolation | 1 | 2012 | 365 | 0.090 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2021 | 2026 | 0.090 |
Why?
|
Mental Health | 2 | 2014 | 3010 | 0.090 |
Why?
|
Social Environment | 1 | 2014 | 1022 | 0.090 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 1 | 2010 | 103 | 0.090 |
Why?
|
Emergency Service, Hospital | 2 | 2021 | 7658 | 0.090 |
Why?
|
Inflammation | 4 | 2022 | 10637 | 0.090 |
Why?
|
Maternal Health Services | 1 | 2014 | 455 | 0.090 |
Why?
|
Telephone | 1 | 2012 | 617 | 0.080 |
Why?
|
Chi-Square Distribution | 1 | 2015 | 3508 | 0.080 |
Why?
|
Communicable Diseases | 1 | 2017 | 880 | 0.080 |
Why?
|
Health Surveys | 1 | 2019 | 4036 | 0.080 |
Why?
|
Child Health Services | 1 | 2014 | 667 | 0.080 |
Why?
|
Acetates | 1 | 2010 | 311 | 0.080 |
Why?
|
India | 1 | 2014 | 2197 | 0.080 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2011 | 638 | 0.080 |
Why?
|
Registries | 4 | 2021 | 8091 | 0.080 |
Why?
|
Population Surveillance | 1 | 2019 | 2616 | 0.080 |
Why?
|
Zinc | 1 | 2012 | 684 | 0.080 |
Why?
|
Peer Group | 1 | 2012 | 635 | 0.080 |
Why?
|
Retina | 1 | 2018 | 2616 | 0.080 |
Why?
|
Superoxides | 4 | 2010 | 387 | 0.080 |
Why?
|
Child | 7 | 2023 | 77709 | 0.080 |
Why?
|
Lipids | 1 | 2019 | 3307 | 0.080 |
Why?
|
Community Health Services | 1 | 2012 | 650 | 0.070 |
Why?
|
Stroke | 3 | 2021 | 9981 | 0.070 |
Why?
|
Health Promotion | 1 | 2019 | 2205 | 0.070 |
Why?
|
Biopsy | 1 | 2019 | 6755 | 0.070 |
Why?
|
Survival Rate | 2 | 2020 | 12788 | 0.070 |
Why?
|
Risk | 3 | 2020 | 9688 | 0.070 |
Why?
|
Community-Acquired Infections | 1 | 2011 | 465 | 0.070 |
Why?
|
Age Distribution | 1 | 2013 | 2902 | 0.070 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2011 | 459 | 0.070 |
Why?
|
Educational Status | 1 | 2015 | 2540 | 0.070 |
Why?
|
Cell Membrane | 1 | 1996 | 3749 | 0.070 |
Why?
|
Curriculum | 1 | 2020 | 3605 | 0.070 |
Why?
|
Calcium | 4 | 2011 | 5755 | 0.070 |
Why?
|
Treatment Outcome | 3 | 2021 | 63107 | 0.070 |
Why?
|
Pandemics | 2 | 2022 | 8385 | 0.060 |
Why?
|
Patient Preference | 1 | 2012 | 889 | 0.060 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2013 | 1381 | 0.060 |
Why?
|
Cytokines | 1 | 2020 | 7323 | 0.060 |
Why?
|
Quinolines | 1 | 2010 | 732 | 0.060 |
Why?
|
Pain Measurement | 1 | 2015 | 3420 | 0.060 |
Why?
|
Antioxidants | 1 | 2013 | 1659 | 0.060 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3229 | 0.060 |
Why?
|
Hodgkin Disease | 1 | 2013 | 1415 | 0.060 |
Why?
|
Logistic Models | 1 | 2019 | 13409 | 0.060 |
Why?
|
Counseling | 1 | 2012 | 1523 | 0.060 |
Why?
|
Patient Education as Topic | 2 | 2012 | 2278 | 0.060 |
Why?
|
Opioid-Related Disorders | 1 | 2019 | 2064 | 0.060 |
Why?
|
Osteoarthritis, Knee | 1 | 2015 | 1222 | 0.060 |
Why?
|
Pregnancy | 3 | 2021 | 29144 | 0.060 |
Why?
|
Data Collection | 1 | 2013 | 3339 | 0.060 |
Why?
|
Inflammation Mediators | 1 | 2013 | 1888 | 0.060 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 3255 | 0.060 |
Why?
|
Immunologic Factors | 1 | 2013 | 1580 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2019 | 14723 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 1 | 2013 | 1790 | 0.060 |
Why?
|
Analgesics, Opioid | 1 | 2019 | 3677 | 0.060 |
Why?
|
Health Behavior | 1 | 2014 | 2635 | 0.050 |
Why?
|
Anti-Bacterial Agents | 2 | 2000 | 7182 | 0.050 |
Why?
|
Prospective Studies | 5 | 2021 | 53290 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2019 | 4468 | 0.050 |
Why?
|
B-Cell Activating Factor | 1 | 2021 | 119 | 0.050 |
Why?
|
Socioeconomic Factors | 2 | 2014 | 7785 | 0.050 |
Why?
|
Spiramycin | 1 | 2000 | 3 | 0.050 |
Why?
|
Insurance, Health | 1 | 2013 | 2494 | 0.050 |
Why?
|
Atrial Fibrillation | 1 | 2019 | 5035 | 0.050 |
Why?
|
Immunoglobulin G | 1 | 1993 | 4561 | 0.050 |
Why?
|
Emotions | 1 | 2012 | 2659 | 0.050 |
Why?
|
Clarithromycin | 2 | 2000 | 86 | 0.050 |
Why?
|
Methotrexate | 2 | 2020 | 1728 | 0.050 |
Why?
|
Myocardial Infarction | 2 | 2021 | 11718 | 0.050 |
Why?
|
Cities | 1 | 2022 | 513 | 0.050 |
Why?
|
Multi-Institutional Systems | 1 | 2019 | 43 | 0.040 |
Why?
|
Pigments, Biological | 1 | 1999 | 53 | 0.040 |
Why?
|
Phenazines | 1 | 1999 | 58 | 0.040 |
Why?
|
Delayed Diagnosis | 1 | 2023 | 441 | 0.040 |
Why?
|
Pleurisy | 1 | 2019 | 53 | 0.040 |
Why?
|
Bacterial Proteins | 4 | 2011 | 3854 | 0.040 |
Why?
|
Influenza, Human | 1 | 2011 | 1479 | 0.040 |
Why?
|
Albumins | 1 | 2022 | 568 | 0.040 |
Why?
|
Dietary Supplements | 1 | 2012 | 3296 | 0.040 |
Why?
|
Hypertension | 1 | 2019 | 8479 | 0.040 |
Why?
|
Depression | 1 | 2018 | 7759 | 0.040 |
Why?
|
Erythrocyte Membrane | 1 | 2000 | 442 | 0.040 |
Why?
|
Heart Failure | 2 | 2021 | 10895 | 0.040 |
Why?
|
Quality of Health Care | 1 | 2014 | 4369 | 0.040 |
Why?
|
Docosahexaenoic Acids | 1 | 2005 | 875 | 0.040 |
Why?
|
Clinical Coding | 1 | 2019 | 171 | 0.040 |
Why?
|
Retrospective Studies | 7 | 2023 | 77460 | 0.040 |
Why?
|
Dinoprostone | 1 | 2001 | 601 | 0.040 |
Why?
|
Cultural Diversity | 1 | 2022 | 359 | 0.040 |
Why?
|
Osteonecrosis | 1 | 2019 | 227 | 0.040 |
Why?
|
Hematologic Tests | 1 | 2019 | 240 | 0.040 |
Why?
|
Roxithromycin | 1 | 1996 | 2 | 0.040 |
Why?
|
Hospital Information Systems | 1 | 2019 | 395 | 0.040 |
Why?
|
Calcimycin | 1 | 1996 | 222 | 0.040 |
Why?
|
Ionophores | 1 | 1996 | 108 | 0.040 |
Why?
|
Zymosan | 1 | 1996 | 124 | 0.040 |
Why?
|
Cytoplasmic Granules | 1 | 1999 | 610 | 0.040 |
Why?
|
Erythromycin | 1 | 1996 | 120 | 0.040 |
Why?
|
Lysophosphatidylcholines | 1 | 1996 | 81 | 0.040 |
Why?
|
Platelet Activating Factor | 1 | 1996 | 149 | 0.040 |
Why?
|
Respiratory Burst | 1 | 1996 | 114 | 0.040 |
Why?
|
Pleural Effusion | 1 | 2019 | 337 | 0.040 |
Why?
|
NF-kappa B | 1 | 2005 | 2499 | 0.030 |
Why?
|
Pancreatic Elastase | 2 | 2010 | 136 | 0.030 |
Why?
|
South Africa | 1 | 2021 | 1731 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2021 | 1200 | 0.030 |
Why?
|
Outpatients | 1 | 2023 | 1487 | 0.030 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 1996 | 821 | 0.030 |
Why?
|
Case-Control Studies | 3 | 2020 | 21748 | 0.030 |
Why?
|
Azithromycin | 1 | 1996 | 196 | 0.030 |
Why?
|
Contraceptives, Oral | 1 | 2017 | 564 | 0.030 |
Why?
|
Atrophy | 1 | 2019 | 1584 | 0.030 |
Why?
|
Luminescent Measurements | 1 | 1996 | 405 | 0.030 |
Why?
|
Propensity Score | 1 | 2021 | 1781 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2022 | 2307 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2021 | 2453 | 0.030 |
Why?
|
Diet | 1 | 2012 | 7937 | 0.030 |
Why?
|
Autoantibodies | 1 | 2021 | 2036 | 0.030 |
Why?
|
Quality Indicators, Health Care | 1 | 2023 | 1831 | 0.030 |
Why?
|
Pneumonia, Viral | 1 | 2011 | 3242 | 0.030 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39052 | 0.030 |
Why?
|
Fibrosis | 1 | 2019 | 2029 | 0.030 |
Why?
|
Toxoids | 1 | 2011 | 12 | 0.030 |
Why?
|
Survival Analysis | 2 | 2015 | 10252 | 0.030 |
Why?
|
Aged, 80 and over | 2 | 2018 | 57776 | 0.030 |
Why?
|
Anti-Asthmatic Agents | 1 | 1996 | 536 | 0.030 |
Why?
|
Pseudomonas aeruginosa | 1 | 1999 | 1219 | 0.030 |
Why?
|
Cyclic AMP | 2 | 2010 | 1472 | 0.030 |
Why?
|
Coronary Artery Bypass | 1 | 2021 | 2288 | 0.030 |
Why?
|
Bronchiectasis | 1 | 1993 | 128 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2022 | 2716 | 0.020 |
Why?
|
Obesity | 3 | 2022 | 12746 | 0.020 |
Why?
|
Quality of Life | 1 | 2012 | 12802 | 0.020 |
Why?
|
Hemolysis | 2 | 2005 | 420 | 0.020 |
Why?
|
Cytochalasin B | 1 | 2010 | 74 | 0.020 |
Why?
|
Rolipram | 1 | 2010 | 27 | 0.020 |
Why?
|
Calcium-Transporting ATPases | 2 | 2001 | 123 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2021 | 2569 | 0.020 |
Why?
|
Bangladesh | 1 | 2012 | 687 | 0.020 |
Why?
|
Mortality | 1 | 2021 | 2864 | 0.020 |
Why?
|
Linear Models | 1 | 2020 | 5953 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2015 | 2971 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2021 | 3778 | 0.020 |
Why?
|
Asthma | 3 | 1996 | 6010 | 0.020 |
Why?
|
Sulfides | 1 | 2010 | 165 | 0.020 |
Why?
|
Albuterol | 1 | 2010 | 208 | 0.020 |
Why?
|
Cyclopropanes | 1 | 2010 | 416 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2021 | 3680 | 0.020 |
Why?
|
Self Report | 1 | 2018 | 3553 | 0.020 |
Why?
|
Regression Analysis | 1 | 2017 | 6459 | 0.020 |
Why?
|
Placebos | 1 | 2012 | 1676 | 0.020 |
Why?
|
Respiratory Sounds | 1 | 2011 | 696 | 0.020 |
Why?
|
Prognosis | 2 | 2019 | 29060 | 0.020 |
Why?
|
Antidepressive Agents | 1 | 2018 | 2838 | 0.020 |
Why?
|
Calcium Channels | 1 | 2010 | 622 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2021 | 4245 | 0.020 |
Why?
|
Antimalarials | 1 | 2013 | 905 | 0.020 |
Why?
|
Depressive Disorder | 1 | 2018 | 3747 | 0.020 |
Why?
|
Drug Interactions | 1 | 2010 | 1460 | 0.020 |
Why?
|
Cystic Fibrosis | 1 | 1993 | 1178 | 0.010 |
Why?
|
Adenosine Triphosphate | 2 | 2001 | 2027 | 0.010 |
Why?
|
Recombinant Proteins | 2 | 2005 | 6621 | 0.010 |
Why?
|
Cells, Cultured | 2 | 2011 | 19233 | 0.010 |
Why?
|
Disease Progression | 1 | 2019 | 13286 | 0.010 |
Why?
|
Animals | 2 | 2013 | 168768 | 0.010 |
Why?
|
Interleukin-8 | 1 | 2005 | 690 | 0.010 |
Why?
|
Forecasting | 1 | 2011 | 2951 | 0.010 |
Why?
|
Cholelithiasis | 1 | 1983 | 414 | 0.010 |
Why?
|
Exercise | 1 | 2017 | 5615 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2022 | 17446 | 0.010 |
Why?
|
Phospholipases A2 | 1 | 2001 | 203 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 25039 | 0.010 |
Why?
|
Phospholipases A | 1 | 2001 | 216 | 0.010 |
Why?
|
Macrophage-1 Antigen | 1 | 2001 | 290 | 0.010 |
Why?
|
Cell Degranulation | 1 | 2001 | 287 | 0.010 |
Why?
|
Body Mass Index | 1 | 2017 | 12721 | 0.010 |
Why?
|
Leukocyte Elastase | 1 | 1999 | 113 | 0.010 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 1 | 2001 | 494 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2012 | 12025 | 0.010 |
Why?
|
Sheep | 1 | 2000 | 1437 | 0.010 |
Why?
|
Membrane Potentials | 1 | 2001 | 1137 | 0.010 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 1999 | 491 | 0.010 |
Why?
|
Potassium | 1 | 2001 | 1336 | 0.010 |
Why?
|
Pneumococcal Infections | 1 | 2001 | 497 | 0.010 |
Why?
|
Peroxidase | 1 | 1999 | 611 | 0.010 |
Why?
|
Sodium | 1 | 1999 | 1622 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2012 | 25628 | 0.010 |
Why?
|
Infant | 1 | 2012 | 35134 | 0.010 |
Why?
|
Escherichia coli | 1 | 2001 | 4217 | 0.010 |
Why?
|
Urban Health | 1 | 1986 | 547 | 0.000 |
Why?
|
Jews | 1 | 1983 | 385 | 0.000 |
Why?
|
Self Care | 1 | 1986 | 786 | 0.000 |
Why?
|
Emergencies | 1 | 1986 | 1170 | 0.000 |
Why?
|
Body Height | 1 | 1983 | 1578 | 0.000 |
Why?
|
Cholesterol | 1 | 1983 | 2919 | 0.000 |
Why?
|
Cost-Benefit Analysis | 1 | 1986 | 5388 | 0.000 |
Why?
|
Body Weight | 1 | 1983 | 4671 | 0.000 |
Why?
|
Blood Glucose | 1 | 1983 | 6254 | 0.000 |
Why?
|